References
- Lemon SM, Institute of Medicine. (U.S.). Committee on a Strategy for Minimizing the Impact of Naturally Occurring Infectious Diseases of Military Importance: Vaccine Issues in the U.S. Military. Protecting our forces: improving vaccine acquisition and availability in the U.S. military. Washington, D.C.: National Academies Press, 2002.
- Artenstein AW, Opal JM, Opal SM, Tramont EC, Peter G, Russell PK. History of U.S. military contributions to the study of vaccines against infectious diseases. Mil Med 2005; 170:Suppl 3 - 11; PMID: 15916278
- Grabenstein JD, Pittman PR, Greenwood JT, Engler RJ. Immunization to protect the US Armed Forces: heritage, current practice, and prospects. Epidemiol Rev 2006; 28:3 - 26; http://dx.doi.org/10.1093/epirev/mxj003; PMID: 16763072
- Kaper J, Rappouli R, Buckley M. Vaccine Development: Current Status and Future Needs. A Report from the American Academy of Microbiology: American Society for Microbiology, 2005.
- Enserink M. Infectious diseases. Massive outbreak draws fresh attention to little-known virus. Science 2006; 311:1085; http://dx.doi.org/10.1126/science.311.5764.1085a; PMID: 16497896
- Kalantri SP, Joshi R, Riley LW. Chikungunya epidemic: an Indian perspective. Natl Med J India 2006; 19:315 - 22; PMID: 17343016
- Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg 2000; 62:681 - 5; PMID: 11304054
- Boudreau EF, Josleyn M, Ullman D, Fisher D, Dalrymple L, Sellers-Myers K, et al. A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome. Vaccine 2012; 30:1951 - 8; http://dx.doi.org/10.1016/j.vaccine.2012.01.024; PMID: 22248821
- Jonsson CB, Figueiredo LTM, Vapalahti O. A global perspective on hantavirus ecology, epidemiology, and disease. Clin Microbiol Rev 2010; 23:412 - 41; http://dx.doi.org/10.1128/CMR.00062-09; PMID: 20375360
- Vapalahti K, Paunio M, Brummer-Korvenkontio M, Vaheri A, Vapalahti O. Puumala virus infections in Finland: increased occupational risk for farmers. Am J Epidemiol 1999; 149:1142 - 51; http://dx.doi.org/10.1093/oxfordjournals.aje.a009769; PMID: 10369509
- DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22:151 - 85; http://dx.doi.org/10.1016/S0167-6296(02)00126-1; PMID: 12606142
- Light DW, Warburton R. Demythologizing the high costs of pharmaceutical research. Biosocieties 2011; 6:34 - 50; http://dx.doi.org/10.1057/biosoc.2010.40
- Aebersold P. FDA Experience with Medical Countermeasures under the Animal Rule. Advances in preventive medicine 2012; 2012:507571.
- Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev 2011; 239:62 - 84; http://dx.doi.org/10.1111/j.1600-065X.2010.00980.x; PMID: 21198665
- Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB. Clinical applications of DNA vaccines: current progress. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2011; 53:296-302.